A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

Trial Profile

A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs RP 4010 (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions
  • Sponsors Rhizen Pharmaceuticals
  • Most Recent Events

    • 14 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 14 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 10 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top